Keyword: Mavyret (glecaprevir and pibrentasvir)
It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.
AbbVie is hitting the road this month to spur veterans toward hepatitis C testing in a cross-country bus tour with the American Legion.
AbbVie is bracing for European biosimilar competition to Humira, but the drug is still continuing its upward trajectory.
Gilead's Epclusa Chinese nod comes just a few weeks after Merck’s Zepatier, and AbbVie's Mavyret is close behind.
Remember the days when AbbVie’s hep C revenues consistently fell short? Those are long gone.
The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead.
Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.
The benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S.
Hepatitis C dominated the discussion on Gilead's third-quarter earnings call—and it wasn’t a positive discussion.
Get set for even more competition in the hep C space as AbbVie picked up FDA approval for Mavyret.